Central precocious puberty: treatment with triptorelin 11.25 mg

Area of Science:

• Pediatric Endocrinology
• Reproductive Medicine
• Pharmacology

Background:

• Limited data exist on quarterly GnRH analog treatment for central precocious puberty (CPP).
• Evaluating novel treatment regimens is crucial for managing CPP effectively.

Purpose of the Study:

• To assess the efficacy of a 11.25 mg triptorelin dose administered quarterly in children diagnosed with CPP.
• To determine the impact of this treatment on hormonal profiles and pubertal progression.

Main Methods:

• A cohort of 17 pediatric patients (16 female) with CPP received triptorelin 11.25 mg every 90 days.
• Hormonal levels (gonadotropins, gonadal steroids) and pubertal signs were monitored at baseline and at 3, 6, and 12 months.

Main Results:

• All patients achieved suppressed luteinizing hormone (LH) peaks (<3 IU/L) and prepubertal estradiol levels by 3 months.
• Mean LH peak values significantly decreased from 25.7 IU/L at baseline to 0.9 IU/L at 3 months (P < 0.0001).
• Hormonal suppression was maintained through 12 months of treatment.

Conclusions:

• Triptorelin 11.25 mg administered quarterly is an effective treatment for suppressing the pituitary-gonadal axis in children with CPP.
• The treatment demonstrates rapid and sustained efficacy from the first administration.